...
首页> 外文期刊>The Journal of Neuroscience: The Official Journal of the Society for Neuroscience >A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression.
【24h】

A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression.

机译:p38丝裂原活化蛋白激酶在5-羟色胺转运蛋白调控中的作用:转运蛋白表面表达所涉及的不同细胞机制的证据。

获取原文
获取原文并翻译 | 示例
           

摘要

The serotonin transporter (SERT) is regulated by various signaling mechanisms that may operate to maintain appropriate levels of synaptic serotonin (5-HT). We demonstrate that one of the mitogen-activated protein kinases (MAPKs), p38 MAPK, regulates SERT. Treatment of rat midbrain synaptosomes with p38 MAPK-specific inhibitors, PD169316 [4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole] or SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole] , reduced 5-HT uptake. An additive SERT inhibition by PD169316 and beta-phorbol 12-myristate 13-acetate (beta-PMA) indicated the involvement of a protein kinase C (PKC)-independent MAPK pathway. Kinetic studies indicated a significant decrease in the transport capacity (V(max)) after PD169316 treatment of synaptosomes. Biotinylation studies showed reduced SERT proteins in the plasma membrane of synaptosomes after p38 MAPK inhibition and PKC activation. Phosphorylation studies using synaptosomes revealed decreased SERT phosphorylation by PD169316 but increased phosphorylation by beta-PMA. d-Amphetamine enhanced SERT basal phosphorylation and PD169316 blocked this effect. SERT interaction with protein phosphatase 2A catalytic subunit and syntaxin 1A decreased after PD169316 or beta-PMA treatment of synaptosomes. In synaptosomes, PKC activation but not p38 MAPK inhibition resulted in SERT redistribution from cholesterolrich lipid raft fractions to nonlipid raft fractions. The presence of phospho-p38 MAPK in synaptosomes and human embryonic kidney 293 (HEK-293) cells suggested the presence of constitutively active p38 MAPK in these preparations. Cotransfection of HEK-293 cells with SERT and a constitutively active form of MAP kinase kinase 3b(E) [MKK3b(E)] increased 5-HT transport, and RNA interference targeted to p38 MAPK inhibited 5-HT uptake, confirming the involvement of active p38 MAPK in SERT expression. Although PD169316 inhibited SERT insertion to the plasma membrane, beta-PMA increased SERT internalization in HEK-293 cells. Together, these results indicate a distinct role of p38 MAPK in SERT regulation.
机译:血清素转运蛋白(SERT)受各种信号机制的调节,这些信号机制可维持适当水平的突触血清素(5-HT)。我们证明有丝分裂原激活的蛋白激酶(MAPKs),p38 MAPK之一,调节SERT。用p38 MAPK特异性抑制剂PD169316 [4-(4-氟苯基)-2-(4-硝基苯基)-5-(4-吡啶基)-1H-咪唑]或SB203580 [4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑],降低了5-HT的吸收。 PD169316和β-佛波醇12-肉豆蔻酸酯13-乙酸酯(β-PMA)对SERT的累加抑制表明涉及蛋白激酶C(PKC)依赖性MAPK途径。动力学研究表明PD169316处理突触体后转运能力(V(max))明显降低。生物素化研究表明,p38 MAPK抑制和PKC激活后,突触体质膜中的SERT蛋白减少。使用突触小体的磷酸化研究表明,PD169316减少了SERT磷酸化,但β-PMA增加了磷酸化。 d-苯丙胺增强了SERT的基础磷酸化作用,PD169316阻止了该作用。 PD169316或β-PMA处理突触体后,与蛋白磷酸酶2A催化亚基和语法1A的SERT相互作用降低。在突触体中,PKC激活而不是p38 MAPK抑制导致从富含胆固醇的脂筏部分到非脂筏部分的SERT重新分布。突触小体和人胚胎肾293(HEK-293)细胞中存在磷酸化p38 MAPK,提示这些制剂中存在组成型活性p38 MAPK。 HEK-293细胞与SERT和MAP激酶激酶3b(E)[MKK3b(E)]的组成型活性形式的共转染增加了5-HT的转运,靶向p38 MAPK的RNA干扰抑制了5-HT的吸收,证实了SERT表达中有活性的p38 MAPK。尽管PD169316抑制了SERT插入质膜,但β-PMA增加了HEK-293细胞中SERT的内在化。在一起,这些结果表明p38 MAPK在SERT调节中的独特作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号